Acute Tumor Response to ZD6126 Assessed by Intrinsic Susceptibility Magnetic Resonance Imaging
Open Access
- 1 May 2005
- Vol. 7 (5), 466-474
- https://doi.org/10.1593/neo.04622
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Vascular‐targeting therapies for treatment of malignant diseaseCancer, 2004
- Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126Clinical Cancer Research, 2004
- Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumorsJournal of Magnetic Resonance Imaging, 2004
- MRI for assessing antivascular cancer treatmentsThe British Journal of Radiology, 2003
- Tumor vascular architecture and function evaluated by non‐invasive susceptibility MRI methods and immunohistochemistryJournal of Magnetic Resonance Imaging, 2003
- The biology of the combretastatins as tumour vascular targeting agentsInternational Journal of Experimental Pathology, 2002
- Theory of NMR signal behavior in magnetically inhomogeneous tissues: The static dephasing regimeMagnetic Resonance in Medicine, 1994
- Evaluation of the susceptibility effect on gradient echo phase images in vivo: A sequential study of intracerebral hematomaMagnetic Resonance Imaging, 1992
- EFFECT OF BROMOCRIPTINE ON DNA SYNTHESIS, GROWTH AND HORMONE SECRETION OF SPONTANEOUS PITUITARY TUMOURS IN THE RATJournal of Endocrinology, 1981